Fact-checked by Grok 2 weeks ago

Polyneuropathy

Polyneuropathy is a neurological disorder characterized by damage or dysfunction affecting multiple peripheral nerves, typically in a symmetric pattern that begins in the distal extremities such as the feet and hands, leading to sensory, motor, and autonomic impairments.^[1] It represents the most common type of peripheral nervous system disorder in adults, particularly among the elderly, with prevalence estimates ranging from about 2% in the general population to 5-8% in older adults.^[1]^[2] This condition encompasses over 100 distinct types, including diabetic sensorimotor polyneuropathy, chronic inflammatory demyelinating polyneuropathy (CIDP), and hereditary forms like Charcot-Marie-Tooth disease.^[3] The primary causes of polyneuropathy include metabolic disorders such as diabetes mellitus, which accounts for the majority of cases in developed countries and affects up to 50% of individuals with long-standing diabetes.^[2] Other etiological factors encompass nutritional deficiencies (e.g., vitamins B1, B6, and B12), chronic alcohol misuse (prevalent in 22% to 66% of alcoholics), exposure to toxins or chemotherapy agents (affecting 30% to 40% of patients receiving certain drugs), infections like HIV or Lyme disease, autoimmune conditions such as Guillain-Barré syndrome or lupus, and inherited genetic mutations (with over 80 identified for hereditary neuropathies).^[4]^[1]^[3] Risk factors that exacerbate susceptibility include uncontrolled diabetes, repetitive trauma from occupational activities, kidney or liver disease, and hypothyroidism.^[4] Clinically, polyneuropathy often manifests as a distal symmetric sensorimotor syndrome, with initial symptoms including numbness, tingling (paresthesia), and burning pain in the extremities, which may progress to muscle weakness, loss of coordination, and falls.^[1] Autonomic involvement can lead to complications like orthostatic hypotension, gastrointestinal dysmotility, or abnormal sweating, while severe cases may result in ulcers, infections, or permanent disability due to reduced sensation and mobility.^[4] Diagnosis typically involves a thorough medical history, neurological examination, blood tests for underlying causes (e.g., HbA1c for diabetes), electromyography (EMG), nerve conduction studies, and occasionally nerve biopsy.^[3]^[2] Management of polyneuropathy focuses on addressing the underlying etiology, such as glycemic control for diabetic cases or abstinence from alcohol, alongside symptomatic treatments including medications like gabapentin or pregabalin for neuropathic pain, physical therapy to improve strength and balance, and in immune-mediated forms like CIDP, immunomodulatory therapies such as intravenous immunoglobulin (IVIg) or corticosteroids.^[2]^[1] Ongoing research as of 2025 explores neuroprotective agents and stem cell therapies for nerve regeneration.^[5] Early intervention is crucial to prevent progression, though complete reversal is often limited, emphasizing the importance of preventive strategies in at-risk populations.^[3]

Definition and Classification

Definition

Polyneuropathy is a disorder of the peripheral nervous system involving simultaneous damage to multiple peripheral nerves, typically manifesting in a symmetric and distal pattern that leads to sensory, motor, or autonomic dysfunction.^[6] This condition is most commonly length-dependent, meaning it preferentially affects the longest axons first, such as those innervating the distal extremities like the feet and hands, due to the increased metabolic demands and vulnerability of these extended nerve fibers.^[7]^[8] Unlike mononeuropathy, which is confined to a single peripheral nerve often due to focal compression or trauma, or radiculopathy, which arises from damage to spinal nerve roots and produces dermatomal or myotomal patterns, polyneuropathy features widespread, bilateral involvement of the peripheral nerves beyond any single nerve or root distribution.^[9]^[2] The peripheral nervous system encompasses sensory fibers responsible for transmitting tactile, pain, and temperature sensations; motor fibers that innervate skeletal muscles for voluntary movement; and autonomic fibers that control involuntary processes such as heart rate and digestion.^[3] In polyneuropathy, the pathological process generally initiates distally in these fiber types within the longest nerves, progressing proximally as the disease advances.^[10] The term polyneuropathy emerged in the early 20th century to characterize these diffuse peripheral nerve disorders, reflecting advances in neurological classification at the time.^[1]

Classification

Polyneuropathies are classified based on several key criteria to facilitate diagnosis and management, including the temporal course of progression, the predominant fiber types affected, and electrodiagnostic patterns observed in nerve conduction studies. This multifaceted approach highlights the heterogeneity of the condition while aiding in distinguishing between subtypes.^[11]^[2]^[6] In terms of temporal course, polyneuropathies are categorized as acute, subacute, or chronic. Acute forms develop rapidly over days, often peaking within four weeks, as exemplified by Guillain-Barré syndrome, an immune-mediated disorder leading to ascending weakness. Subacute polyneuropathies progress over weeks to a few months before stabilizing, such as in certain paraneoplastic sensory neuropathies. Chronic variants evolve gradually over months to years, including progressive conditions like chronic inflammatory demyelinating polyneuropathy (CIDP).^[11]^[2]^[6] Classification by fiber-type involvement further delineates the clinical manifestations. Sensory polyneuropathies primarily affect sensory nerves, resulting in predominant numbness and paresthesias. Motor polyneuropathies target motor fibers, causing muscle weakness and atrophy. Sensorimotor types involve both sensory and motor components, which is common in many acquired forms. Autonomic polyneuropathies disrupt involuntary functions, leading to symptoms like orthostatic hypotension or gastrointestinal dysmotility. These categories often overlap, with sensorimotor being the most frequent pattern in chronic cases.^[11]^[2]^[6] Electrodiagnostic studies, including nerve conduction velocities and electromyography, provide a pathologic classification into axonal, demyelinating, or mixed forms. Axonal polyneuropathies involve degeneration of the nerve axon itself, often seen in toxic or metabolic etiologies, with reduced amplitudes but relatively preserved conduction velocities. Demyelinating types feature damage to the myelin sheath, resulting in slowed conduction velocities and conduction block, as in Guillain-Barré syndrome or CIDP. Mixed patterns combine features of both, complicating prognosis and treatment. This classification correlates with underlying mechanisms but shows etiologic overlap, such as inflammatory processes in demyelinating cases or toxic exposures in axonal ones.^[11]^[2]^[6] Common subtypes include distal symmetric polyneuropathy, the most prevalent form characterized by a length-dependent, stocking-glove distribution of symptoms, often linked to diabetes or idiopathic causes. Small-fiber polyneuropathy selectively affects thinly myelinated and unmyelinated fibers, manifesting as burning pain and autonomic dysfunction without significant motor involvement, and is frequently underdiagnosed via standard electrodiagnostics. Distal symmetric polyneuropathy accounts for the majority of chronic cases, with diabetic neuropathy representing a leading example.^[11]^[2]^[6]

Epidemiology

Prevalence and Incidence

Polyneuropathy affects approximately 1% to 7% of the general adult population worldwide, with prevalence estimates varying based on diagnostic criteria and study methodologies.^[12] In population-based studies, the age-standardized prevalence is around 4%, rising significantly with age to about 7% in individuals over 65 years. For example, a 2016 Dutch cohort study of middle-aged and elderly participants reported an overall prevalence of 5.5% for definite polyneuropathy, increasing to higher rates in older subgroups. Among those with diabetes, particularly type 2, the prevalence is substantially elevated, reaching up to 50% in some cohorts due to the condition's role as a major contributor.^[13] A 2024 cross-sectional study in Mexico City adults aged 40-65 reported a prevalence of 14.6% using the Michigan Neuropathy Screening Instrument, indicating higher rates when including symptomatic cases.^[14] Incidence rates of polyneuropathy are estimated at 0.5 to 1 per 1,000 person-years in the general population, but they increase in older adults to approximately 8 per 1,000 person-years.^[12] In elderly populations, annual incidence is approximately 8 per 1,000 person-years, particularly when comorbidities such as diabetes are present, though exact figures depend on surveillance methods.^[15] In regions like sub-Saharan Africa, prevalence estimates range from 0.8 to 2.5 per 1,000, with incidence similarly low but rising with associated conditions like nutritional deficiencies or infections.^[12] Geographic variations show higher prevalence in developed countries, attributed to aging populations and higher diabetes rates, compared to underreported cases in low-resource settings where access to neurological evaluation is limited.^[12] Overall trends indicate an increasing burden, driven by global rises in diabetes prevalence and population aging.

Risk Factors

Risk factors for polyneuropathy can be broadly categorized as non-modifiable and modifiable, with the former including inherent demographic and genetic elements that cannot be altered, while the latter encompass lifestyle, environmental, and medical conditions amenable to intervention.^[12] Among non-modifiable factors, advancing age represents a primary risk, with prevalence rising sharply after age 50 and reaching approximately 7-8% in individuals over 65 years, compared to lower rates in younger populations.^[16] Genetic predisposition plays a key role in hereditary forms, such as Charcot-Marie-Tooth disease, where family history confers a prevalence of 40-82 cases per 100,000 individuals.^[12] Sex shows variation by subtype, with a slight male predominance observed in inflammatory polyneuropathies like chronic inflammatory demyelinating polyneuropathy (CIDP), where males are affected at rates up to twice that of females.^[17] Modifiable risk factors are prominent contributors, led by diabetes mellitus, the strongest overall association, with odds ratios ranging from 2 to 4 for developing polyneuropathy and accounting for 18-49% of chronic cases.^[18] Chronic alcohol abuse, particularly exceeding 100 grams per day, elevates risk with a relative risk of approximately 3.9 (95% CI 1.5-9.0) and contributes to 3-19% of cases.^[12]^[19] Obesity, defined as BMI greater than 30 kg/m², increases susceptibility, with odds ratios reported around 3 in some studies, often in conjunction with metabolic syndrome.^[20] Vitamin deficiencies, notably B12 and E, underlie 1-9% of polyneuropathies and are preventable through dietary or supplemental means.^[12] Occupational and environmental exposures further heighten risk, including toxins such as pesticides and heavy metals, which account for a subset of cases through cumulative damage.^[12] Chemotherapy-induced peripheral neuropathy (CIPN) affects 30-40% of patients receiving neurotoxic agents, representing a significant iatrogenic risk in cancer treatment.^[21] Comorbid conditions amplify vulnerability, with chronic kidney disease linked to 2-4% of cases, hypothyroidism similarly contributing 2-4%, and infections like HIV or leprosy serving as notable precipitants in endemic areas.^[12]^[22] Interactions between factors can compound risk, such as polypharmacy in patients with diabetes, where medications like statins may interact to exacerbate neuropathy beyond individual effects.^[23] These elements collectively explain variations in polyneuropathy prevalence across populations.^[12]

Clinical Presentation

Symptoms

Patients with polyneuropathy often report a range of sensory disturbances, primarily affecting the extremities in a distal symmetric pattern known as the stocking-glove distribution. Common complaints include paresthesias, such as tingling or a "pins and needles" sensation, which typically begin in the toes and fingers before progressing proximally.^[3]^[4] Numbness is another frequent symptom, where individuals describe a loss of sensation as if wearing gloves or stockings, impairing their ability to detect touch, vibrations, or position sense.^[16] Dysesthesias, including abnormal sensations like burning or heightened sensitivity, further contribute to discomfort, with allodynia causing pain from non-painful stimuli such as light touch.^[11] Neuropathic pain affects approximately one-third of patients with polyneuropathy and is characterized by sharp, jabbing, throbbing, or burning qualities that often worsen at night.^[16] This pain can be evoked by touch or temperature changes and is particularly prominent in small-fiber predominant forms, where it occurs without associated muscle weakness.^[3] In sensorimotor types, such pain may correlate with emerging motor symptoms, though sensory complaints predominate initially.^[11] Autonomic symptoms arise from involvement of nerves controlling involuntary functions and include orthostatic hypotension, leading to dizziness or lightheadedness upon standing due to blood pressure drops.^[4] Other manifestations encompass gastroparesis, resulting in delayed stomach emptying and digestive difficulties; erectile dysfunction in males; and anhidrosis, or reduced sweating, which can cause heat intolerance.^[11] Symptoms of polyneuropathy typically start distally in the longest nerves and ascend gradually, reflecting a length-dependent progression that may span days to years depending on the underlying cause.^[3] In small-fiber variants, patients experience predominant pain and sensory loss without early motor involvement.^[16] These subjective experiences significantly impair quality of life, with nocturnal pain and sensory disruptions commonly causing sleep disturbances and reduced daily functioning.^[4] Advanced cases can lead to severe disability, affecting mobility and independence in a substantial proportion of individuals.^[11]

Signs

Polyneuropathy manifests through various observable physical signs during clinical examination, primarily affecting sensory, motor, and autonomic functions in a distal, symmetric pattern known as the "stocking-glove" distribution.^[11]^[6] Sensory signs are often the earliest and most prominent, involving deficits in both large and small nerve fibers. Reduced vibration sense and proprioception, assessed using a tuning fork applied to the toes or ankles, indicate large-fiber involvement and may lead to sensory ataxia with positive Romberg sign.^[6]^[11] Hypoesthesia to pinprick and temperature stimuli, tested by applying a safety pin or warm/cold objects along the extremities, reflects small-fiber dysfunction.^[16] Deep tendon reflexes, particularly ankle jerks, are commonly diminished or absent, further supporting sensory nerve impairment.^[6] The 10-g monofilament test detects tactile hypoesthesia in small-fiber polyneuropathy by identifying areas of reduced pressure sensation on the feet.^[11] Motor signs typically emerge later and involve symmetric distal weakness, starting with toe extensors and progressing to ankle dorsiflexors, resulting in foot drop and a characteristic steppage gait where patients high-step to avoid tripping.^[6]^[11] In chronic cases, muscle atrophy becomes evident in the distal lower limbs, such as thinning of the calves, while fasciculations are rare and suggest alternative diagnoses if prominent.^[11] Autonomic signs vary by involvement but include fixed or sluggishly reactive pupils due to impaired pupillary reflexes, anhidrosis leading to dry skin, and orthostatic hypotension evidenced by a systolic blood pressure drop greater than 20 mmHg upon standing.^[24]^[11] These signs collectively hint at slowed nerve conduction velocities without requiring formal electrophysiologic testing at the bedside.^[6] Severity is graded clinically from mild, where only sensory deficits are present with preserved ambulation, to severe, involving profound motor weakness necessitating wheelchair use.^[25]^[11]

Etiology

Acquired Causes

Acquired causes of polyneuropathy encompass a wide range of non-genetic etiologies and are the most common. These etiologies are often grouped by underlying mechanisms, including metabolic derangements, toxic exposures, inflammatory or infectious processes, nutritional deficiencies, and paraneoplastic or idiopathic origins. Early identification of these causes is crucial, as many are treatable or reversible if addressed promptly.^[2] Metabolic causes are among the most prevalent, with diabetic polyneuropathy representing the leading etiology, affecting up to 60% of individuals with long-standing diabetes and typically manifesting as a distal symmetric sensorimotor neuropathy.^[26] Uremic neuropathy arises in end-stage kidney disease due to the accumulation of uremic toxins that impair nerve function.^[27] Hypothyroidism can also induce a reversible polyneuropathy through slowed nerve conduction and demyelination, often improving with thyroid hormone replacement.^[28] Toxic causes frequently result from environmental or therapeutic exposures, with chronic alcohol abuse leading to a predominantly axonal neuropathy that overlaps with nutritional deficiencies from poor diet.^[19] Chemotherapy-induced peripheral neuropathy (CIPN), especially from platinum-based agents like cisplatin and oxaliplatin, affects 70% to 100% of patients treated with these agents and presents as a dose-dependent sensory neuropathy with potential for persistence post-treatment.^[29] Heavy metal toxicities, such as from lead or arsenic, cause a mixed axonal and demyelinating neuropathy detectable via urine heavy metal screening.^[30] Inflammatory and infectious causes often involve immune-mediated or direct pathogen-related nerve damage. Guillain-Barré syndrome (GBS) is an acute, post-infectious autoimmune polyneuropathy characterized by rapid-onset ascending weakness and areflexia, frequently triggered by Campylobacter jejuni or viral infections.^[9] Chronic inflammatory demyelinating polyneuropathy (CIDP) represents a chronic autoimmune variant with progressive or relapsing weakness and sensory loss, responsive to immunomodulatory therapies.^[31] In infectious settings, HIV-associated distal symmetric polyneuropathy impacts 30-50% of advanced cases, while leprosy causes a multifocal neuropathy due to Mycobacterium leprae invasion of peripheral nerves.^[32]^[33] Nutritional deficiencies contribute to polyneuropathy in settings of malnutrition or malabsorption, with vitamin B12 deficiency leading to subacute combined degeneration, featuring sensory ataxia and proprioceptive loss from dorsal column and peripheral nerve involvement.^[34] Thiamine (vitamin B1) deficiency manifests as beriberi neuropathy, a progressive axonal sensorimotor polyneuropathy seen in alcoholics or those with restricted diets, which can mimic Guillain-Barré syndrome if acute.^[34]^[35] Paraneoplastic polyneuropathies arise in association with underlying malignancies, often small-cell lung cancer, where anti-Hu antibodies target neuronal nuclear antigens, resulting in a subacute sensory neuronopathy or mixed sensorimotor neuropathy.^[36] Idiopathic cases, comprising 20-30% of polyneuropathies, remain unexplained after thorough evaluation and may involve subtle undetected factors.^[12]

Hereditary Causes

Hereditary polyneuropathies encompass a diverse group of genetic disorders affecting the peripheral nervous system, primarily through mutations that disrupt myelin formation, axonal integrity, or neuronal function. These conditions are distinguished by their inherited nature, often identified through family history, which helps differentiate them from acquired forms. Over 100 genes have been implicated, with inheritance patterns including autosomal dominant (the most common, accounting for the majority of cases), autosomal recessive, and X-linked modes, alongside variable penetrance in some variants. Onset typically occurs in childhood or adolescence and progresses slowly over decades. The most prevalent hereditary polyneuropathy is Charcot-Marie-Tooth (CMT) disease, with an estimated global prevalence of approximately 1 in 2,500 individuals. CMT is classified into subtypes based on nerve conduction studies and genetic etiology; CMT type 1 is primarily demyelinating and often results from a duplication of the PMP22 gene on chromosome 17, leading to abnormal myelin sheath formation. In contrast, CMT type 2 is axonal in nature and frequently caused by mutations in the MFN2 gene, which encodes mitofusin 2, a protein essential for mitochondrial fusion and axonal transport. Hereditary transthyretin amyloidosis (hATTR) represents another significant genetic cause, driven by mutations in the TTR gene that result in misfolded transthyretin protein deposition as amyloid fibrils in nerves and tissues. This form predominantly affects sensory and autonomic nerves, causing progressive length-dependent polyneuropathy with features such as painful paresthesias, orthostatic hypotension, and gastrointestinal dysmotility. Over 130 TTR mutations have been identified, with the Val30Met variant being the most common worldwide and often presenting in adulthood. Other notable hereditary polyneuropathies include Friedreich's ataxia, caused by expansions in the FXN gene (encoding frataxin, a mitochondrial protein) and characterized by spinocerebellar degeneration alongside a sensory axonopathy. This autosomal recessive disorder typically manifests in early adolescence with gait ataxia and absent deep tendon reflexes due to large-fiber sensory loss. Hereditary neuropathy with liability to pressure palsies (HNPP), resulting from a deletion in the PMP22 gene, predisposes individuals to recurrent focal neuropathies triggered by minor trauma or compression, with an autosomal dominant inheritance pattern.

Pathophysiology

General Mechanisms

Polyneuropathy involves damage to multiple peripheral nerves, primarily through shared pathological processes that affect axons and myelin sheaths. These mechanisms include axonal degeneration, demyelination, and impaired regeneration, often initiated by metabolic stress, toxins, or energy deficits that exploit the vulnerability of long nerve fibers.^[37] A predominant pattern in polyneuropathy is length-dependent axonopathy, characterized by a "dying-back" process where degeneration begins at the distal ends of the longest axons, such as those in the lower extremities, and progresses proximally. This occurs due to the increased susceptibility of distal segments to metabolic stress and toxins, which impair axonal transport and lead to accumulation of damaged organelles. The dying-back phenomenon results from slowed or disrupted transport of essential proteins and mitochondria, causing energy failure and cytoskeletal breakdown in the nerve terminals.^[37] Following axonal injury, Wallerian degeneration ensues, involving the rapid breakdown of the distal axonal segment disconnected from the cell body. This process is mediated by calcium influx, activation of proteases like calpains, and subsequent clearance by macrophages, which remove myelin debris and axonal fragments to prepare for potential repair. In chronic polyneuropathies, a Wallerian-like degeneration can occur without overt trauma, driven by persistent energy failure in axons that depletes protective factors such as NAD+, leading to progressive fragmentation similar to classical Wallerian changes.^[38]^[37] Demyelination represents another core mechanism, stemming from dysfunction of Schwann cells, the myelinating glia of the peripheral nervous system. Impaired Schwann cell function disrupts myelin sheath formation and maintenance, resulting in segmental demyelination that exposes axons to the extracellular environment. This leads to conduction block, where nerve impulses fail to propagate, and slowed conduction velocities due to the loss of saltatory conduction along myelinated fibers.^[39] Peripheral nerve regeneration is limited in humans, with axons regrowing at an average rate of 1 mm per day under optimal conditions, often insufficient for full functional recovery in polyneuropathy. This slow process is further hindered by fibrosis and scarring at injury sites, which create physical barriers to axonal outgrowth and disrupt the alignment of regenerating fibers.^[40] Disruption of the blood-nerve barrier exacerbates these mechanisms by compromising the selective permeability that normally shields peripheral nerves from circulating immune cells and toxins. Breakdown of tight junctions in endoneurial microvessels and perineurium allows influx of harmful substances, promoting inflammation and further nerve injury across various polyneuropathies.^[41]

Cause-Specific Processes

In diabetic polyneuropathy, chronic hyperglycemia triggers oxidative stress through the overactivation of metabolic pathways, including the polyol pathway, where aldose reductase converts excess glucose to sorbitol, leading to intracellular accumulation that causes osmotic stress and depletion of NADPH, thereby promoting reactive oxygen species (ROS) production and cellular damage.^[42] This oxidative imbalance further exacerbates mitochondrial dysfunction and advanced glycation end-product formation, contributing to axonal degeneration in a length-dependent manner.^[43] Additionally, hyperglycemia induces microvascular ischemia by damaging endoneurial vessels, reducing nerve blood flow and oxygen delivery, which amplifies neuronal injury.^[44] In inflammatory polyneuropathies such as chronic inflammatory demyelinating polyneuropathy (CIDP) and Guillain-Barré syndrome (GBS), autoantibodies target myelin components, with anti-ganglioside antibodies in GBS subtypes binding to Schwann cell surfaces and initiating complement activation via the classical pathway.^[45] This complement deposition disrupts the blood-nerve barrier and recruits macrophages, which invade the perineurium and phagocytose myelin sheaths, leading to segmental demyelination and conduction block.^[46] In CIDP, persistent autoantibody-mediated inflammation sustains macrophage infiltration and T-cell involvement, resulting in repeated cycles of demyelination and ineffective remyelination.^[47] Alcoholic polyneuropathy arises from both direct neurotoxicity of ethanol and its metabolites, which impair mitochondrial function and induce oxidative damage to axons, and from thiamine (vitamin B1) deficiency, which disrupts energy metabolism and axonal transport mechanisms.^[48] Ethanol's direct effects include interference with microtubule assembly and fast axonal transport, leading to distal axonal swelling and degeneration, while thiamine deficiency exacerbates this by inhibiting pyruvate dehydrogenase activity and causing energy failure in neurons.^[49] These processes often combine to produce a predominantly sensory, length-dependent axonopathy.^[50] In hereditary polyneuropathies like Charcot-Marie-Tooth disease type 1 (CMT1), particularly CMT1A, duplication of the peripheral myelin protein 22 (PMP22) gene leads to overexpression of PMP22 in Schwann cells, triggering endoplasmic reticulum stress and apoptosis of these cells during myelination.^[51] This Schwann cell dysfunction results in hypomyelination and segmental demyelination, with surviving Schwann cells proliferating aberrantly to form concentric onion bulb structures around denuded axons on nerve biopsy.^[52] The mutant PMP22 alters myelin compaction and stability, perpetuating a cycle of demyelination and incomplete repair.^[53] Amyloid polyneuropathy involves the misfolding and extracellular deposition of amyloid proteins, such as transthyretin or light chains, which form fibrillar aggregates that infiltrate nerve fascicles and compress axons and vessels.^[54] These deposits disrupt endoneurial architecture, leading to focal ischemia from vascular occlusion and direct mechanical compression of nerve fibers, resulting in axonal loss without primary demyelination.^[55] The progressive accumulation exacerbates nerve ischemia and secondary Wallerian degeneration distally.^[56] Idiopathic small-fiber polyneuropathy is characterized by selective degeneration of small unmyelinated C-fibers and thinly myelinated Aδ-fibers, often involving loss of dorsal root ganglion (DRG) neurons without evidence of demyelination on standard testing.^[57] This neuronopathy-like process may stem from non-length-dependent ganglionitis or direct DRG cell injury, leading to reduced intraepidermal nerve fiber density and sensory dysfunction, distinct from large-fiber involvement.^[58] The absence of demyelination underscores a primary axonal or neuronal pathology in these cases.^[59]

Diagnosis

Clinical Evaluation

The clinical evaluation of polyneuropathy begins with a detailed history-taking to characterize the patient's symptoms and identify potential etiologies. Key elements include the onset and duration of symptoms, which may be acute (over days), subacute (over weeks), or chronic (over months to years), as well as the distribution pattern, typically symmetric and distal in length-dependent polyneuropathies but potentially asymmetric in other forms.^[6] Exposures to toxins, medications (such as chemotherapy agents), or alcohol should be assessed, alongside family history to screen for hereditary conditions like Charcot-Marie-Tooth disease, and comorbidities such as diabetes mellitus or chronic kidney disease, which are common contributors.^[16]^[6] Certain features in the history raise red flags warranting urgent specialist referral. Rapid progression may suggest underlying malignancy or acute inflammatory processes, while asymmetry often points to vasculitic or multifocal etiologies.^[16] Cranial nerve involvement, such as facial weakness or dysphagia, is particularly concerning for conditions like Guillain-Barré syndrome.^[16]^[6] The physical examination follows a structured neurological protocol to confirm polyneuropathy and assess severity. This includes evaluation of muscle strength, typically revealing distal weakness; sensory testing for modalities like light touch, pinprick, vibration (using a 128-Hz tuning fork), and proprioception, often showing a stocking-glove distribution; and deep tendon reflexes, which are commonly diminished or absent at the ankles.^[16]^[6] Gait assessment is essential to detect sensory ataxia from proprioceptive loss, and autonomic function may be screened via orthostatic blood pressure measurements to identify orthostatic hypotension or other dysautonomia.^[16]^[6] Standardized scoring tools aid in grading the severity of polyneuropathy during evaluation. The Neuropathy Symptom Score (NSS) quantifies patient-reported symptoms such as numbness, tingling, and pain in the lower limbs, with scores ≥1 indicating abnormality and used to track progression, particularly in diabetic polyneuropathy.^[60] The Neuropathy Disability Score (NDS), derived from physical exam findings including ankle reflexes, vibration sense, pinprick, and temperature sensation (maximum score of 10), grades clinical disability, with scores ≥6 suggesting significant neuropathy.^[60] Together, history and physical examination identify an underlying cause in approximately 60% of cases of distal symmetric polyneuropathy, guiding subsequent targeted investigations.^[6]

Diagnostic Tests

Diagnostic tests for polyneuropathy encompass a range of laboratory, electrophysiological, and imaging modalities aimed at confirming the presence of neuropathy, characterizing its type (axonal, demyelinating, or mixed), and identifying underlying etiologies. These tests are selected based on clinical suspicion to provide objective evidence beyond history and examination.^[61] Blood tests form the initial laboratory evaluation to screen for common reversible causes. Measurements of fasting glucose or HbA1c levels help detect diabetes mellitus, a leading cause of acquired polyneuropathy. Vitamin B12 and folate levels are assessed to identify deficiencies that can lead to demyelinating or axonal neuropathies, while serum protein electrophoresis (SPEP) screens for paraproteinemia associated with conditions like monoclonal gammopathy. Inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are evaluated to suggest systemic inflammation or autoimmune processes.^[62]^[63] Electrophysiological studies, including nerve conduction studies (NCS) and electromyography (EMG), are cornerstone tests for most patients with suspected polyneuropathy. NCS measure nerve conduction velocity and compound muscle action potential amplitude to distinguish demyelinating patterns (characterized by slowed velocity) from axonal ones (marked by reduced amplitude). EMG detects denervation through fibrillation potentials and reduced recruitment, confirming active muscle involvement and supporting the classification as axonal or mixed. These studies are typically the first-line electrophysiological approach, particularly for length-dependent symmetric polyneuropathies.^[64]^[65]^[66] For small-fiber neuropathy, which may yield normal NCS and EMG due to involvement of unmyelinated fibers, skin biopsy serves as the gold standard by quantifying intraepidermal nerve fiber density (IENFD). A punch biopsy from the distal leg assesses reduced IENFD, with sensitivity around 90% for confirming small-fiber involvement in symptomatic patients. This method provides histological evidence of fiber loss not detectable by standard electrophysiology. Emerging non-invasive alternatives, such as corneal confocal microscopy, are being explored for assessing small-fiber damage as of 2025.^[67]^[68]^[69] Imaging techniques like magnetic resonance imaging (MRI) and ultrasound aid in excluding mimics such as plexopathy and evaluating specific subtypes. MRI of the spine or brachial plexus identifies root or plexus involvement, helping differentiate polyneuropathy from radiculoplexus disorders. High-resolution ultrasound detects nerve enlargement or cross-sectional area increases, particularly in chronic inflammatory demyelinating polyneuropathy (CIDP), where it reveals multifocal hypertrophic changes.^[70]^[71] Additional specialized tests include lumbar puncture and genetic testing. Cerebrospinal fluid analysis via lumbar puncture often shows elevated protein levels (cytoalbuminologic dissociation) in up to 90% of Guillain-Barré syndrome (GBS) and CIDP cases, without significant pleocytosis, supporting inflammatory demyelination. Genetic testing, such as targeted sequencing for mutations in genes like PMP22 or MPZ, is indicated for suspected hereditary forms to confirm inherited demyelinating or axonal polyneuropathies.^[72]^[73]

Differential Diagnosis

Polyneuropathy must be differentiated from other conditions that present with similar symptoms of sensory disturbance, weakness, or pain in the extremities, as misdiagnosis can lead to inappropriate management. Common peripheral mimics include mononeuritis multiplex, often associated with vasculitis, which features asymmetric involvement of multiple individual nerves rather than the symmetric, length-dependent pattern typical of polyneuropathy; diagnosis is supported by nerve biopsy revealing inflammatory changes in vessel walls.^[16]^[6] Radiculopathy, such as that caused by spinal stenosis, presents with asymmetric, dermatomal sensory loss and motor deficits accompanied by back or neck pain, with nerve conduction studies (NCS) showing normal peripheral findings but radicular abnormalities on electromyography (EMG).^[74]^[16] Central nervous system disorders can also mimic polyneuropathy. Multiple sclerosis typically involves upper motor neuron signs like spasticity, hyperreflexia, and ataxia, along with characteristic brain and spinal cord lesions on magnetic resonance imaging (MRI), distinguishing it from the peripheral lower motor neuron pattern of polyneuropathy.^[74] Vitamin B12 deficiency leading to subacute combined degeneration causes sensory ataxia and spasticity due to myelopathy, with additional hematologic or gastrointestinal clues and abnormal serum B12 levels, rather than isolated peripheral nerve involvement.^[6] Myopathies, in contrast, primarily affect muscles and present with symmetric proximal weakness without sensory symptoms, elevated creatine kinase (CK) levels, and myopathic changes on EMG, helping to exclude neuropathic processes.^[16]^[6] Non-neurologic conditions may simulate neuropathic pain or discomfort. Fibromyalgia involves diffuse, widespread musculoskeletal pain with characteristic tender points but lacks objective neurologic deficits and shows normal NCS/EMG results.^[74]^[16] Erythromelalgia is characterized by episodic burning pain in the feet or hands accompanied by skin flushing and warmth, without sensory loss or NCS abnormalities, and often responds to cooling or vasodilators.^[16] Key features aiding differentiation include the symmetry and distal distribution of symptoms in polyneuropathy versus asymmetry or proximal predominance in mimics, along with NCS/EMG patterns such as diffuse axonal loss in polyneuropathy compared to multifocal or radicular changes elsewhere; response to specific therapies, like immunosuppression for vasculitis, can further clarify the diagnosis.^[74]^[16] Despite thorough evaluation, approximately 25% of cases of distal symmetric polyneuropathy remain idiopathic, with no identifiable cause after standard testing.^[16]^[6]

Management

Underlying Cause Treatment

Treatment of polyneuropathy focuses on addressing the underlying etiology to halt or reverse nerve damage, with efficacy varying by cause. For metabolic etiologies, such as diabetes, intensive glycemic control targeting an HbA1c level below 7% has been shown to reduce the risk of neuropathy progression by approximately 60% in patients with type 2 diabetes, based on longitudinal studies linking sustained lower HbA1c to decreased complications.^[75] In uremic polyneuropathy associated with chronic kidney disease, initiation of dialysis can prevent further progression in some patients, particularly when started early, while renal transplantation offers the most effective reversal of symptoms.^[76] For hypothyroidism-related polyneuropathy, levothyroxine replacement therapy normalizes thyroid function and improves neurological symptoms.^[77] Inflammatory causes, including Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), respond well to immunomodulatory therapies. Intravenous immunoglobulin (IVIG) at doses of 2 g/kg over 2-5 days or plasmapheresis yields improvement rates of 60-80% in CIDP patients, with randomized trials demonstrating significant disability reduction compared to placebo.^[78] For CIDP, corticosteroids such as prednisone at 1 mg/kg daily induce remission in up to 70% of cases, though long-term use requires monitoring for side effects.^[79] Toxic and nutritional polyneuropathies require removal of the offending agent and nutritional support. In alcoholic polyneuropathy, alcohol cessation combined with high-dose thiamine supplementation (up to 300 mg daily) can reverse early axonal damage, as supported by clinical observations of symptom improvement following abstinence and vitamin repletion.^[80] For heavy metal toxicity, such as lead or arsenic exposure, chelation therapy with agents like EDTA or DMSA facilitates metal excretion and halts progression, with case series showing neurological recovery in acute exposures.^[81] In chemotherapy-induced peripheral neuropathy (CIPN), duloxetine at 60 mg daily prevents severe symptoms in patients receiving oxaliplatin or paclitaxel, reducing incidence by 30-50% in phase III trials.^[82] Infectious etiologies are managed by targeting the pathogen. For HIV-associated polyneuropathy, antiretroviral therapy suppresses viral load and stabilizes or improves neuropathy in most patients, with early initiation preventing distal sensory progression.^[83] Leprosy-related polyneuropathy responds to multidrug therapy including dapsone (100 mg daily), which eradicates Mycobacterium leprae and arrests nerve damage, achieving cure rates over 95% when combined with rifampicin and clofazimine.^[84] Paraneoplastic polyneuropathy, often linked to small-cell lung cancer, is best addressed by treating the underlying tumor. Chemotherapy regimens such as etoposide and platinum-based agents lead to neurological stabilization or improvement in 50-70% of cases, with tumor response correlating directly to symptom amelioration.^[85] Randomized controlled trials across etiologies indicate that cause-directed therapies halt polyneuropathy progression in 50-70% of cases, underscoring the importance of early identification and intervention over symptomatic measures alone.^[6]

Symptomatic Therapy

Symptomatic therapy for polyneuropathy focuses on alleviating pain, improving motor function, and managing autonomic symptoms through established, non-disease-modifying interventions. Pain, a common and debilitating feature, is primarily addressed with first-line pharmacological agents including gabapentinoids such as gabapentin at doses of 900-3600 mg/day, which provides at least 50% pain relief in one out of every six patients (NNT=6).^[86] Serotonin-norepinephrine reuptake inhibitors (SNRIs) like duloxetine at 60 mg/day are also recommended as initial therapy, offering similar efficacy with an NNT of approximately 6 for significant pain reduction in neuropathic conditions.^[87] Tricyclic antidepressants (TCAs), such as low-dose amitriptyline (10-25 mg/day), serve as an alternative first-line option, particularly when other agents are contraindicated, due to their comparable analgesic effects in peripheral neuropathic pain.^[88] Topical treatments, including capsaicin 8% patches applied for 30-60 minutes or lidocaine 5% patches, provide localized relief for peripheral symptoms with minimal systemic absorption, supported by evidence in diabetic and other polyneuropathies.^[89] For motor impairments like weakness and foot drop, physical therapy emphasizes strengthening exercises, balance training, and gait improvement to enhance mobility and prevent falls, forming a cornerstone of non-pharmacological support.^[90] Orthotic devices, such as ankle-foot orthoses (AFOs), are routinely prescribed to stabilize the ankle and support dorsiflexion, reducing gait instability in patients with distal weakness.^[91] Autonomic symptoms, including orthostatic hypotension, are managed with midodrine (typically 2.5-10 mg three times daily) to vasoconstrict and elevate blood pressure, improving standing tolerance.^[92] Compression measures like thigh-high elastic stockings further aid venous return and symptom control, often used in combination for optimal effect.^[93] The American Academy of Neurology (AAN) 2022 guidelines, applicable to painful polyneuropathy, advocate a multimodal approach integrating pharmacological, physical, and supportive therapies tailored to patient factors like comorbidities and preferences, with opioids reserved as a last resort due to risks of dependency and limited long-term efficacy.^[94] Monitoring for adverse effects is essential; for instance, gabapentinoids commonly cause dizziness in about 20% of patients, necessitating dose adjustments or discontinuation to maintain safety.^[95] This symptomatic strategy complements but does not replace treatments targeting the underlying cause.

Emerging Therapies

Stem cell therapy, particularly using mesenchymal stem cells (MSCs), represents a promising regenerative approach for polyneuropathy, especially in diabetic peripheral neuropathy (DPN). MSCs promote nerve regeneration by modulating inflammation, supporting axonal growth, and improving nerve conduction velocity. A 2024 systematic review of human studies indicated that MSC therapy yields significant improvements in clinical outcomes for DPN, including enhanced nerve conduction and sensory parameters, with benefits observed across multiple trials.^[96] Phase I/II trials, such as those evaluating umbilical cord-derived MSCs, have demonstrated safety and preliminary efficacy in reducing neuropathic pain and improving glycemic control in diabetic patients, though larger phase III studies are needed to confirm long-term regeneration effects.^[97] Non-opioid analgesics are advancing as targeted options for neuropathic pain in polyneuropathy, addressing limitations of traditional therapies like opioids. Related non-opioid candidates, such as suzetrigine, have reported clinically meaningful pain reductions in phase II studies for acute neuropathic conditions, supporting the shift toward mechanism-specific inhibitors.^[98] Cannabinoids, including combinations of cannabidiol (CBD) and tetrahydrocannabinol (THC), offer neuroprotective and analgesic effects for polyneuropathy-related pain through modulation of the endocannabinoid system. A 2025 meta-analysis of cannabinoid administration for pain, including neuropathic subtypes, found a modest treatment effect with reductions in subjective pain scores, though placebo responses were notable.^[99] Transdermal THC:CBD formulations demonstrated significant symptom relief in DPN patients in a 2024 randomized trial, with improvements in pain intensity and quality of life, and such combos have gained approval in select countries like Canada for refractory neuropathic pain.^[100] Inhaled cannabis therapies also showed sustained efficacy over long-term use in diabetic neuropathy cohorts, per 2025 clinical assessments.^[101] For chemotherapy-induced peripheral neuropathy (CIPN), recombinant thrombomodulin (ART-123) is emerging as a preventive agent by reducing vascular endothelial damage and inflammation during oxaliplatin-based regimens. A phase III trial launched in Japan in 2025 evaluates ART-123's efficacy in colorectal cancer patients, building on phase II data showing decreased incidence of severe neuropathy.^[102] Prior placebo-controlled studies confirmed its role in mitigating oxaliplatin-induced peripheral neuropathy without compromising chemotherapy outcomes.^[103] This approach addresses a critical gap in CIPN management, where current options remain limited. Gene therapies for hereditary polyneuropathy, such as RNA interference (RNAi) agents targeting transthyretin (TTR), continue to evolve with expanded applications. Patisiran, a TTR silencer, maintains efficacy in halting polyneuropathy progression in hereditary ATTR amyloidosis, with five-year open-label extension data from 2025 confirming sustained neurological benefits and safety. The U.S. FDA approved expansion to cardiomyopathy indications in 2024, with ongoing real-world studies supporting its use in diverse ATTRv variants, including V122I, for polyneuropathy stabilization.^[104]^[105] Nanomaterials enhance gene and drug delivery in polyneuropathy by enabling targeted crossing of the blood-nerve barrier; for instance, polymeric nanoparticles loaded with neuroprotective agents showed promise in 2024 preclinical models for CIPN treatment via transdermal routes.^[106] Emerging nanotechnology platforms in 2025 aim to improve bioavailability and reduce off-target effects in hereditary forms.^[107] Despite these advances, emerging therapies for polyneuropathy face challenges including limited randomized controlled trials (RCTs), which hinder robust efficacy data, and access issues due to high costs and regulatory hurdles. A 2025 expert consensus highlighted barriers in translating preclinical successes to clinical practice, such as suboptimal trial designs and fragmented care pathways that delay patient enrollment.^[108] These gaps underscore the need for international collaboration to accelerate approvals and broaden availability, particularly for rare hereditary subtypes.^[109]

Prognosis

Outcomes

The outcomes of polyneuropathy vary significantly depending on the underlying etiology, with recovery prospects influenced by the timeliness of intervention and the specific pathological mechanism involved. In general, appropriate management leads to partial improvement in many cases, though full recovery is less common in chronic forms.^[110] For acute forms such as Guillain-Barré syndrome (GBS), the prognosis is relatively favorable with prompt treatment; approximately 80% of patients regain mobility within 6-12 months, while 5-10% experience permanent disability.^[111]^[112] Most recovery occurs within the first year, with treatments like intravenous immunoglobulin or plasmapheresis enhancing nerve regeneration in demyelinating variants.^[113] In chronic acquired polyneuropathy, such as diabetic polyneuropathy, the disease course is typically one of slow progression over years, with rigorous glycemic control stabilizing symptoms in a substantial proportion of patients and potentially preventing further deterioration.^[114] Mortality is elevated compared to the general diabetic population, primarily due to associated systemic complications rather than the neuropathy itself.^[115] Hereditary polyneuropathies, exemplified by Charcot-Marie-Tooth (CMT) disease, follow a lifelong trajectory with variable progression; symptoms often progress gradually, leading to moderate disability over decades in many cases, though life expectancy remains unaffected.^[116] Demyelinating subtypes like CMT1A show slower deterioration than axonal forms, with gradual muscle weakness and sensory loss accumulating over decades.^[117] Key prognostic factors include the timing of diagnosis and the predominant pathology: early intervention can substantially improve outcomes through preservation of nerve function, while demyelinating polyneuropathies generally exhibit better regeneration potential than axonal ones due to less irreversible damage.^[118]^[119] Life expectancy is generally unaffected in most forms of polyneuropathy, except in severe untreated cases linked to underlying conditions like advanced diabetes or renal failure.^[4] Functional outcomes are commonly assessed using scales such as the Overall Neuropathy Limitations Scale (ONLS), which quantifies disability in upper and lower limbs on a 0-12 point range, with higher scores indicating greater limitations in daily activities.^[120]

Complications

Polyneuropathy significantly elevates the risk of falls and related injuries due to sensory deficits and gait instability, with studies reporting that up to 23 times more patients with peripheral neuropathy experience falls compared to those without, and prevalence rates of increased fall risk ranging from 20% to over 50% in diabetic polyneuropathy cohorts.^[121]^[122] In diabetic patients, sensory loss contributes to foot ulcers, which substantially heighten amputation risk—estimated at 15 to 46 times greater than in non-diabetics—due to impaired protective sensation and poor wound healing.^[123] Autonomic dysfunction in polyneuropathy predisposes individuals to cardiovascular complications, including arrhythmias and silent myocardial infarction, where pain is absent or unrecognized. The prevalence of silent myocardial infarction among those with cardiac autonomic neuropathy ranges from 10% to 20%, with higher rates (up to 38%) in patients exhibiting autonomic dysfunction compared to 5% in those without.^[124] Chronic pain associated with polyneuropathy often progresses to a syndrome involving central sensitization, where amplified central nervous system responses exacerbate pain perception beyond peripheral nerve damage. This mechanism is prevalent in neuropathic conditions, contributing to persistent symptoms in a substantial subset of patients.^[125] Severe motor involvement in polyneuropathy can lead to significant disability, with 10% to 30% of patients in advanced forms, such as chronic inflammatory demyelinating polyneuropathy, requiring wheelchair use due to progressive weakness and mobility loss. Additionally, the condition is linked to high rates of depression and anxiety, affecting approximately 40% of individuals with associated chronic pain.^[126]^[127] Systemic complications arise from underlying etiologies, as seen in uremic polyneuropathy where end-stage kidney disease exacerbates nerve damage through toxin accumulation, potentially worsening renal failure and overall morbidity.^[27] Rehabilitation programs, including balance and strength training, can mitigate these complications by improving gait stability and reducing fall risk, with interventions shown to decrease fall incidence by up to 40% in at-risk populations. These efforts also positively influence long-term outcomes by limiting disability progression. As of 2025, emerging therapies such as novel non-opioid analgesics and gene therapies for hereditary forms show promise in improving prognosis.^[128]^[129]

References

[1]
Polyneuropathies - PMC - PubMed Central - NIH
Feb 9, 2018 · Polyneuropathies (peripheral neuropathies) are the most common type of disorder of the peripheral nervous system in adults, and specifically in the elderly.Clinical Presentation And... · Diabetic Neuropathy · Immune-Mediated Neuropathies
[2]
Peripheral Neuropathy | National Institute of Neurological Disorders ...
Aug 7, 2024 · Peripheral neuropathy refers to the many conditions that involve damage to the peripheral nervous system.Charcot-Marie-Tooth Disease · Guillain-Barré Syndrome · Friedreich Ataxia
[3]
Neuropathy - StatPearls - NCBI Bookshelf - NIH
Oct 15, 2022 · Peripheral neuropathies encompass disorders of peripheral nerve cells and fibers, manifesting secondary to a wide range of pathologies.Continuing Education Activity · Etiology · Evaluation · Treatment / Management
[4]
Peripheral neuropathy - Symptoms and causes - Mayo Clinic
Sep 2, 2023 · Peripheral neuropathy happens when the nerves that are located outside of the brain and spinal cord (peripheral nerves) are damaged.Diagnosis and treatment · Hypothyroidism · Anti-seizure medications
[5]
Diagnosis and management of patients with polyneuropathy - PMC
Feb 13, 2023 · KEY POINTS. Polyneuropathy is a common neurologic condition with a variety of subtypes that involve the motor, sensory or autonomic fibres.Figure 1 · Table 1 · How Is The Cause Of An...
[6]
Distal symmetric polyneuropathy: A definition for clinical research
Jan 24, 2005 · The polyneuropathy must begin in the feet. Symmetric indicates that the symptoms and signs are the same on both sides of the body. Persistent or ...Process · Evidence Based Conclusions... · Consensus-Based Principles
[7]
Pathogenesis of Distal Symmetrical Polyneuropathy in Diabetes - PMC
Jul 19, 2022 · DSPN is known as a “length-dependent” neuropathy because it is thought to begin in the distal nerve endings of the longest neurons in the limbs ...
[8]
Peripheral neuropathy: the importance of rare subtypes - PMC
Oct 31, 2016 · Distal symmetric polyneuropathy (DSP), mononeuropathy, and lumbar/cervical radiculopathy are the most common peripheral neuropathies and have ...
[9]
Diagnostic and Therapeutic Advances: Distal Symmetric ...
Nov 28, 2016 · One of the most common localization is a diffuse, length-dependent process called distal symmetric polyneuropathy (DSP).
[10]
Polyneuropathy - Neurologic Disorders - Merck Manuals
A polyneuropathy is a diffuse peripheral nerve disorder that is not confined to the distribution of a single nerve or a single limb and typically is relatively ...
[11]
The epidemiology and risk factors of chronic polyneuropathy - PMC
Polyneuropathy is a disabling condition of the peripheral nerves, characterized by symmetrical distal numbness and paresthesia, often accompanied with pain ...Door-To-Door Survey Studies... · Table 2 · Table 3<|control11|><|separator|>
[12]
Diabetic polyneuropathy and pain, prevalence, and patient...
Diabetic polyneuropathy (DPN) is a serious diabetes complication. Previous studies have reported a wide range of prevalence from 26% to 50% for DPN, 1,25,37,38, ...
[13]
Diagnosis and management of patients with polyneuropathy - CMAJ
Feb 13, 2023 · Polyneuropathy is a common neurologic condition with an overall prevalence in the general population of about 1%–3%, increasing to roughly 7% ...
[14]
Peripheral neuropathy develops with other conditions - UCLA Health
Jun 14, 2023 · The condition is estimated to affect between 8% and 10% of people over the age of 50. However, it's not a direct result of the aging process.
[15]
Chronic inflammatory demyelinating polyneuropathy: Etiology ...
Jun 17, 2025 · There is a predominance in males, with a sex rate ... No specific predisposing risk factors for CIDP have been clearly identified [7].
[16]
Risk Factors and Comorbidities in Diabetic Neuropathy - NIH
Major risk factors of DSPN include diabetes duration, hyperglycemia, and age, followed by prediabetes, hypertension, dyslipidemia, and obesity.<|control11|><|separator|>
[17]
Alcoholic Neuropathy - StatPearls - NCBI Bookshelf - NIH
Dec 30, 2022 · Alcoholic neuropathy is one of the most common adverse effects of chronic alcohol consumption. There is damage to the nerves due to the direct toxic effect of ...
[18]
Chemotherapy-induced peripheral neuropathy: A current review
Jun 5, 2017 · Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its ...
[19]
Chronic Inflammatory Demyelinating Polyradiculoneuropathy in ...
CIDP can coexist with a variety of diseases such as diabetes, MGUS, SLE, and other connective tissue diseases such as Sjogren's syndrome, active hepatitis, HIV, ...
[20]
An update on drug-drug interactions in older adults living with ...
A higher burden of comorbidities in older PWH increases the risk of polypharmacy, typically defined as the daily use of ≥5 medications. In HIV-positive ...Missing: polyneuropathy | Show results with:polyneuropathy
[21]
Peripheral Neuropathy: Evaluation and Differential Diagnosis - AAFP
Dec 15, 2020 · Early peripheral neuropathy may present as sensory alterations that are often progressive, including sensory loss, numbness, pain, or burning ...Missing: impact | Show results with:impact
[22]
Autonomic Neuropathy Clinical Presentation - Medscape Reference
Aug 15, 2022 · An important finding on sensory examination is a stocking and glove pattern of sensory loss, which suggests concurrent somatic neuropathy.History · Physical
[23]
Neuropathies - Physiopedia
[4] Classification methods for PN include: Categorisation based on the number of nerves affected - mono-neuropathies, multifocal neuropathies, poly- ...Missing: temporal etiology
[24]
Diabetic Peripheral Neuropathy - StatPearls - NCBI Bookshelf - NIH
Feb 25, 2024 · Several causes of PN exist, but diabetes mellitus is the most common etiology. Other underlying etiologies include: Alcohol use disorder [10].
[25]
Global hotspots and trends in diabetic peripheral neuropathy ...
Aug 9, 2024 · The above-described diseases include chronic inflammatory demyelinating polyneuropathy, B12 deficiency, hypothyroidism, and uremia, which should ...
[26]
Chemotherapy‐induced neuropathies—a growing problem for ...
Chemotherapy‐induced polyneuropathies are one of the most common side effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunction.Missing: alcohol | Show results with:alcohol
[27]
Peripheral Neuropathy Due to Vitamin Deficiency, Toxins, and ... - NIH
Heavy Metals. Exposure to several metals has been shown to cause peripheral neuropathy and may be discovered on laboratory testing of a 24-hour urine sample.
[28]
Molecular, Electrophysiological, and Ultrasonographic Differences ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common autoimmune neuropathy that can be monophasic, progressive, or relapsing. The ...
[29]
Peripheral Nervous System Manifestations of Infectious Diseases
Distal symmetric polyneuropathy (DSP) associated with HIV is the most common PNS complaint, affecting up to 30% to 50% of patients with advanced infection.Missing: CIDP | Show results with:CIDP
[30]
Acute and chronic neuropathies - PMC - PubMed Central - NIH
Jul 25, 2020 · Leprosy was once one of the more common causes of neuropathy worldwide but is rarer now that the disease is confined to just a few tropical ...
[31]
Nutritional Neuropathies - PMC - PubMed Central - NIH
The most common cause of B12 deficiency is pernicious anemia. ... Postgastrectomy polyneuropathy with thiamine deficiency is identical to beriberi neuropathy.
[32]
Dry Beriberi Manifesting as Acute Inflammatory Demyelinating ...
Oct 31, 2020 · Dry beriberi is a nutritional neuropathy that results from thiamine (vitamin B1) deficiency and is most commonly seen in individuals with a ...
[33]
Utility of anti-Hu Antibodies in the Diagnosis of Paraneoplastic ...
Anti-Hu antibodies (Hu-Abs) were positive in 40 patients with paraneoplastic sensory neuropathy (PSN) and in 1 patient with idiopathic sensory neuropathy in ...Missing: polyneuropathy malignancy
[34]
Peripheral polyneuropathy from electrodiagnostic tests: a 10-year ...
The five main causes of polyneuropathy confirmed by EDX testing were inflammatory, hereditary, idiopathic, multifactorial, and diabetic polyneuropathy.
[35]
Mechanisms of Distal Axonal Degeneration in Peripheral ...
Peripheral neuropathy develops as a combination of just six primary mechanisms: altered metabolism, covalent modification, altered organelle function and ...
[36]
Axon degeneration: Molecular mechanisms of a self-destruction ...
Jan 9, 2012 · Events similar to Wallerian axon degeneration also occur in genetic mutants such as pmn that are impaired in axonal transport (Martin et al ...<|control11|><|separator|>
[37]
Peripheral Demyelinating Diseases: From Biology to Translational ...
Mar 18, 2019 · Peripheral demyelinating diseases (PDD) refer to a spectrum of disorders that involves substantial damage to axons and glial cells, particularly Schwann cells ...Abstract · Introduction · PNS Demyelinating Diseases · Emerging Biomarkers of...
[38]
Peripheral Nerve Healing: So Near and Yet So Far - PMC
Axons regenerate at a relatively constant rate of 1 mm per day, or one inch per month, and usually can be followed clinically with an advancing Tinel sign.
[39]
Biology of the Human Blood-Nerve Barrier in Health and Disease
The BNB is required for physiologic homeostasis, including presumed immune-neural crosstalk in health, with structural, molecular and functional alterations ...
[40]
Oxidative Stress in the Pathogenesis of Diabetic Neuropathy
This review explores the concept that diabetes overloads glucose metabolic pathways, resulting in excess free radical production and oxidative stress.Oxidative Stress In The... · V. Production Of Ros In... · Vii. Biomarkers Of Oxidative...
[41]
Understanding Diabetic Neuropathy: Focus on Oxidative Stress
Aug 3, 2020 · Hyperglycaemia-induced oxidative stress remains the most accepted mechanism for the progression of diabetes to diabetic neuropathy.
[42]
Diabetic peripheral neuropathy: pathogenetic mechanisms and ...
DPN results from oxidative stress, mitochondrial dysfunction, and other metabolic pathways. Hyperglycemia, dyslipidemia, insulin resistance, and microvascular ...
[43]
Evolving understanding of Guillain-Barré syndrome pathophysiology ...
May 13, 2025 · In GBS, binding of C1q to antibodies bound to peripheral nerves activates the classical complement pathway directly on the nerve surface, ...Missing: immunopathogenesis invasion
[44]
The role of macrophages in immune-mediated damage to the ...
The pathological hallmark of the demyelinating autoimmune neuropathies, mainly GBS and CIDP, is a process termed macrophage-mediated demyelination, where ...
[45]
Macrophages and Autoantibodies in Demyelinating Diseases - PMC
Apr 8, 2021 · Myelin phagocytosis by macrophages has been an essential feature of demyelinating diseases in the central and peripheral nervous systems.
[46]
Alcohol-Induced Neuropathy in Chronic Alcoholism: Causes ...
Oct 23, 2020 · These include direct or indirect effects of alcohol metabolites, impaired axonal transport, suppressed excitatory nerve pathway activity, or ...
[47]
Alcoholic neuropathy: possible mechanisms and future treatment ...
Oct 11, 2011 · Chronic alcohol consumption produces painful peripheral neuropathy for which there is no reliable successful therapy, mainly due to lack of ...
[48]
ALCOHOL-RELATED PERIPHERAL NEUROPATHY: NUTRITIONAL ...
Alcohol-related peripheral neuropathy (ALN) is a potentially debilitating complication of alcoholism that results in sensory, motor, and autonomic ...
[49]
Regulation of Schwann cell proliferation and apoptosis in PMP22 ...
Abstract. Charcot–Marie–Tooth disease type 1A (CMT1A) is caused by an increased dosage of the peripheral myelin protein 22 (PMP22) gene or by point mutatio.
[50]
https://pmc.ncbi.nlm.nih.gov/articles/PMC4551507/
[51]
Clinical and Pathological Variation of Charcot-Marie-Tooth 1A in a ...
Charcot-Marie-Tooth 1A (CMT1A) caused by peripheral myelin protein 22 (PMP22) gene duplication is the most common form of hereditary polyneuropathy.
[52]
Amyloid Neuropathy: From Pathophysiology to Treatment in Light ...
Jun 24, 2024 · Amyloidosis is a protein misfolding disease that occurs when a protein fails to acquire its soluble functional fold and deposits in tissues in ...Missing: compression ischemia
[53]
Amyloid Proteins and Peripheral Neuropathy - PMC - PubMed Central
Amyloid-forming proteins may cause tissue dysregulation and damage, including damage to nerves, and may be a common cause of neuropathy in these, and ...
[54]
Neurodegeneration in familial amyloid polyneuropathy
Several hypotheses have been raised to explain axonal and neuronal loss: (i) compression of the nervous tissue by amyloid; however, a cause–effect relationship ...
[55]
Biomarkers in small fiber neuropathy - Open Exploration Publishing
As opposed to axonopathy in LD-SFN, NLD-SFN is caused by selective ganglionitis or neuronitis involving dorsal root ganglion cells that aid the function of ...
[56]
Small fiber neuropathy - Finsterer - 2022 - Wiley Online Library
Feb 7, 2022 · Small fiber neuropathy (SFN) is a disorder of the peripheral nervous system (PNS) due to affection of small nerve fibers, which include Aδ- ...4 Etiology · 7 Treatment · 7.2 Pathophysiologic...
[57]
Small Fiber Neuropathy - StatPearls - NCBI Bookshelf
Dec 12, 2022 · Small fiber neuropathy presents with burning pain, often beginning in the extremities, most notably in the feet. It is due to the involvement of A-delta and C ...
[58]
Scoring systems to screen for diabetic peripheral neuropathy - PMC
Neuropathy disability score (NDS) and neuropathic impairment score in the lower limbs (NIS‐LL). The NDS can be used to assess the signs of neuropathy by 35 ...
[59]
Electrodiagnostic Evaluation of Peripheral Neuropathy - NCBI - NIH
Jan 30, 2023 · This activity reviews some of the causes of peripheral neuropathy and the corresponding electrodiagnostic findings.
[60]
Consensus disease definitions for neurologic immune-related ...
Jul 19, 2021 · Serum testing: HbA1c, TSH, vitamin B12, SPEP/IFE, CK ... Additional laboratory testing guided by neuropathy phenotype: ANCA, ANA, ESR ...
[61]
Evaluation and management of acute high-grade immunotherapy ...
HbA1c, TSH, folate, vitamins B6 and B12, SPEP/IFE, and CK should be used to identify reversible metabolic causes of neuropathy. The guidelines recommend ...
[62]
Nerve Conduction Studies and Electromyography - StatPearls - NCBI
Feb 10, 2025 · NCS and EMG can help confirm the diagnosis of peripheral neuropathy and determine whether it is demyelinating, axonal, or mixed. NCVs, including ...
[63]
Nerve conduction studies in polyneuropathy - PubMed
Nerve conduction studies provide essential information on (1) the spatial pattern of neuropathy, (2) the pattern of abnormalities distinguishing between ...
[64]
Distal Sensorimotor Neuropathy: Improvements in Diagnosis - PMC
DSPN was defined as a symmetrical, length-dependent sensorimotor polyneuropathy attributable to metabolic and microvascular alterations resulting from chronic ...
[65]
Intraepidermal Nerve Fiber Density as an Indicator of Neuropathy ...
May 23, 2025 · ... Skin spot biopsy is the gold standard for diagnosing small fiber neuropathy. A systematic approach to intraepidermal nerve fiber density ...
[66]
Skin biopsy for diagnosis of small fiber neuropathy - PubMed
Conclusion: Detection of reduced IENFD using skin biopsy may be sensitive and specific for clinically-defined syndromes consistent with small fiber neuropathy.
[67]
Low interrater reliability of brachial plexus MRI in chronic ... - NIH
Magnetic resonance imaging (MRI) of the brachial plexus can be helpful to diagnose inflammatory neuropathies such as chronic inflammatory demyelinating ...
[68]
An overview of clinical applications and imaging findings - PMC
Oct 31, 2022 · High-resolution ultrasound of peripheral neuropathies in rheumatological patients: An overview of clinical applications and imaging findings.
[69]
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Apr 26, 2016 · Approximately 90 % of patients with CIDP demonstrate elevated CSF protein (greater than 45 mg/dL) (62-64). CSF pleocytosis is not typically seen ...Missing: genetic | Show results with:genetic
[70]
Differential Diagnosis of Acquired and Hereditary Neuropathies in ...
Aug 9, 2021 · 3. Definition and Classification of Neuropathies in Children and Adolescents. Neuropathies are diseases of the peripheral and cranial nerves, ...
[71]
Peripheral Neuropathy: Differential Diagnosis and Management
Apr 1, 2010 · The term peripheral neuropathy is usually used to describe symmetric and universal damage to adjacent nerves. The damage and clinical ...
[72]
Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot ...
Indeed, intensive glycemic control and lower levels of HbA1c are followed by a reduction in diabetic complications: in HbA1c, <7% is associated a 60% reduction ...
[73]
Uremic neuropathy | MedLink Neurology
Chronic dialysis may prevent neuropathy in some patients, especially if begun early. Renal transplantation is generally the most successful method to prevent ...
[74]
Thyroid hormone replacement therapy in dialysis/renal insufficiency ...
Feb 24, 2025 · This article reviews the mechanism of hypothyroidism in dialysis/renal insufficiency patients and describes the importance and precautions of thyroid hormone ...Missing: polyneuropathy | Show results with:polyneuropathy
[75]
Peripheral neuropathies: current evidence for alternative treatment ...
Reviews and retrospective studies have reported the rate of response to these treatments at between 60 and 70% of patients 10,15, while a study of IVIg alone ...
[76]
AIDP/CIDP Part 2: Treatment | PM&R KnowledgeNow - AAPM&R
Dec 14, 2022 · Approximately 30% to 60% of patients with CIDP treated with mainstay therapies will substantially improve.
[77]
Alcoholic neuropathy: MedlinePlus Medical Encyclopedia
Apr 16, 2025 · Alcoholic neuropathy is damage to the nerves that results from excessive drinking of alcohol.Missing: cessation | Show results with:cessation
[78]
Toxic neuropathies: a practical approach
Alcohol-related peripheral neuropathy: a systematic review ... Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy.
[79]
Duloxetine for prevention and treatment of chemotherapy ... - PubMed
Sep 8, 2022 · Duloxetine has previously been reported to be promising in the setting of chemotherapy-induced peripheral neuropathy (CIPN).Missing: chelation heavy metals
[80]
Peripheral nerve complications of HIV-1 infection - MedLink Neurology
Isoniazid for the treatment of tuberculosis and dapsone for the treatment ... treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.<|separator|>
[81]
Dapsone - StatPearls - NCBI Bookshelf
Jan 31, 2024 · Dapsone is an antibiotic medication used in multidrug regimens and approved by the United States Food and Drug Administration (FDA) for treating leprosy and ...
[82]
Paraneoplastic neurological syndromes of small cell lung cancer
Jul 11, 2024 · Managing the underlying tumor is the best treatment approach for most paraneoplastic syndromes. Therefore, early diagnosis of small cell lung ...
[83]
Gabapentin for Chronic Neuropathic Pain - TheNNT
The NNT for gabapentin is similar to a recent meta ... Gabapentin dosing for neuropathic pain: evidence from randomized placebo-controlled clinical trials.
[84]
Duloxetine for treating painful neuropathy or chronic pain - PubMed
Oct 7, 2009 · Duloxetine at 60 mg daily is effective in treating painful diabetic peripheral neuropathy in the short-term to 12 weeks with a risk ratio (RR) for 50% pain ...
[85]
Amitriptyline for neuropathic pain in adults - PMC - PubMed Central
Amitriptyline is a tricyclic antidepressant that is widely used to treat chronic neuropathic pain (pain due to nerve damage).
[86]
Topical Capsaicin for Neuropathic Pain #255 - PMC - NIH
Topical capsaicin has shown analgesic benefits in postherpetic neuralgia, painful polyneuropathies including diabetic and HIV-related neuropathy, and ...
[87]
Peripheral neuropathy - Diagnosis and treatment - Mayo Clinic
Sep 2, 2023 · Learn what may cause the prickling, tingling or numb sensations of nerve damage and how to prevent and treat this painful disorder.Care at Mayo Clinic · Acupuncture · Doctors and departments
[88]
Foot Drop - StatPearls - NCBI Bookshelf
May 1, 2025 · Foot drop is a neuromuscular condition characterized by weakness or paralysis of the dorsiflexor muscles, causing difficulty lifting the forefoot during gait.
[89]
Midodrine in neurogenic orthostatic hypotension. A new treatment
Midodrine, a new specific alpha-1-agonist has been shown to produce arteriolar constriction and decrease in venous pooling via a constriction of venous ...
[90]
Autonomic neuropathy - Diagnosis & treatment - Mayo Clinic
Jul 7, 2022 · Compression garments. A binder worn around the waist or thigh-high compression stockings may help improve blood flow. Medications to raise ...
[91]
Oral and Topical Treatment of Painful Diabetic Polyneuropathy
In patients with PDN, clinicians should offer TCAs, SNRIs, gabapentinoids, and/or sodium channel blockers to reduce pain (Level B) and consider factors other ...
[92]
https://pubmed.ncbi.nlm.nih.gov/7690383/
[93]
Human studies of the efficacy and safety of stem cells in the ...
Nov 19, 2024 · Stem cell therapy shows significant promise in improving clinical outcomes for DPN, with evident benefits in nerve conduction and sensory parameters.Missing: phase II<|separator|>
[94]
Mesenchymal stem cell-based therapy for type 1 & 2 diabetes ... - NIH
Jun 3, 2025 · Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial.
[95]
The Lipid Receptor G2A (GPR132) Mediates Macrophage Migration ...
Nerve injury-induced neuropathic pain is difficult to treat and mechanistically characterized by strong neuroimmune interactions, involving signaling lipids ...
[96]
Vertex Announces Results From Phase 2 Study of Suzetrigine for ...
Dec 19, 2024 · The study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS).Missing: NX- 13 ROCK2
[97]
Effects of Cannabinoid Administration for Pain: A Meta-Analysis and ...
Oct 9, 2025 · To provide meta-analytic clarification regarding cannabis's impact on subjective pain, we identified studies that assessed drug-induced pain ...
[98]
Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD ...
Nov 14, 2024 · This novel transdermal medical cannabis formulation (THC:CBD:CBN) demonstrated significant therapeutic efficacy in ameliorating painful DPN symptoms while ...<|separator|>
[99]
Long-Term Efficacy and Safety of Inhaled Cannabis Therapy for ...
Sep 30, 2025 · This study examines an inhaled cannabis treatment for painful diabetic neuropathy through clinical trial assessments of pain relief, together ...
[100]
Start of phase III study of ART-123 (Recomodulin™) in Japan for the ...
The phase III study will assess the efficacy of ART-123 for CIPN in patients diagnosed with colorectal cancer and undergoing chemotherapy ...
[101]
A placebo-controlled, double-blind, randomized study of ...
Sep 23, 2020 · A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy
[102]
Five-Year Results With Patisiran for Hereditary Transthyretin ... - NIH
Jan 13, 2025 · This open-label extension of a randomized clinical trial evaluates 5-year safety and efficacy of patisiran for the treatment of hereditary transthyretin ...Missing: indications | Show results with:indications
[103]
Impact of patisiran on polyneuropathy of hereditary transthyretin ...
Sep 20, 2025 · This study assessed the effectiveness and safety of patisiran in patients with V122I/T60A variant transthyretin (ATTRv) amyloidosis with ...Missing: expanded | Show results with:expanded
[104]
Transdermal Delivery of Polymeric Nanoparticles Containing ...
May 31, 2024 · Transdermal Delivery of Polymeric Nanoparticles Containing Aconite Root for the Treatment of Chemotherapy-Induced Peripheral Neuropathy.
[105]
Latest Treatments for Neuropathy: Exploration & Study Data (2025)
For example, nanotechnology-based drug delivery systems could provide targeted and controlled release of medications to affected nerves, ensuring optimal ...
[106]
[PDF] Barriers and new opportunities in developing effective therapies for ...
Jan 22, 2025 · Neuropathic pain is prevalent in. 5–45 % of type 1 diabetes, and in 15–56 % of type 2 diabetes contrasting the prevalence of 7–10 % in the ...
[107]
Barriers and new opportunities in developing effective therapies for ...
Four critical barriers and needs were addressed: (1) Translating bench research to clinical practice, (2) Enhancing clinical trial design, (3) Improving ...
[108]
Media Update: Riliprubart one-year results from phase 2 study ...
Jun 25, 2024 · For SOC-refractory participants, 89% (16/18) improved or remained stable with riliprubart after 24 weeks, with 50% (9/18) showing improvement.
[109]
Facts Your Family Should Know About Guillain-Barré Syndrome in ...
Oct 29, 2025 · IVIg and plasmapheresis are the main therapies; roughly 80% of patients regain mobility within months, though some have lasting symptoms. The ...
[110]
Guillain-Barre syndrome - Diagnosis and treatment - Mayo Clinic
Jun 7, 2024 · About 60% fully recover motor strength one year after diagnosis. About 5% to 10% have very delayed and incomplete recovery. Children rarely ...Symptoms and causes · Doctors and departments · Care at Mayo Clinic
[111]
Guillain‐Barré syndrome: a comprehensive review - PMC
May 30, 2024 · Most patients recover, but approximately one‐third require mechanical ventilation, and 5% die. Disease activity and treatment response are ...
[112]
Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria ...
Oct 1, 2010 · This variety has been shown to be stabilized, perhaps even improved, by rigorous glycemic control. This polyneuropathy has been shown to be ...
[113]
Diabetic neuropathy - Symptoms & causes - Mayo Clinic
Diabetic neuropathy is a type of nerve damage that can happen with diabetes. Blood sugar, also called glucose, becomes high because of diabetes.Diagnosis & treatment · Types of diabetic neuropathy
[114]
Charcot-Marie-Tooth disease - Diagnosis & treatment - Mayo Clinic
Sep 15, 2025 · There's no cure for Charcot-Marie-Tooth disease. But the disease most often worsens slowly. And most often, it doesn't shorten life.<|separator|>
[115]
Disease Course of Charcot-Marie-Tooth Disease Type 2: A 5-Year ...
This prospective study shows a slow deterioration of muscle strength and increase in disability in CMT type 2 during a 5-year follow-up period.
[116]
Early therapy initiation is crucial in chronic inflammatory ...
Jan 7, 2025 · Axonal damage occurs early and is the main cause of clinical disabilities. Prompt initiation of therapy is crucial to prevent axonal damage and ...Neurological Examinations... · Nerve Conduction Studies · Discussion
[117]
Peripheral Polyneuropathy Part 1: Evaluation and Differential ...
Definition. Polyneuropathy refers to pathology affecting multiple peripheral nerves and involves the cell body, axon, myelin sheath, or a combination thereof.
[118]
A modified peripheral neuropathy scale: the Overall ... - NIH
The ONLS therefore shows greater sensitivity to minor disability of the lower limbs. In the ONLS, a score of 0 indicates that a patient has no problems with ...
[119]
Efficacy of Intravenous Immunoglobulin in Patients With IgG ...
Intravenous immunoglobulin therapy was beneficial in 8 (40%) of our 20 patients with polyneuropathy and IgG monoclonal gammopathy of undetermined significance.
[120]
PERIPHERAL NEUROPATHY AS A CAUSE OF FALLS IN THE ...
Nov 3, 1992 · The patients with peripheral neuropathy were 23 times more likely to have fallen during the previous year and were 6 times more likely to have ...Missing: polyneuropathy | Show results with:polyneuropathy<|separator|>
[121]
Fall Risk and Balance Confidence in Patients With Diabetic ...
Oct 23, 2020 · Twenty percent of the DPN patients were at increased risk of falls. Every unit increase in balance confidence was associated with 9% (95% ...
[122]
Diabetic Foot Ulcers: Prevention, Diagnosis and Classification - AAFP
Mar 15, 1998 · The risk of lower extremity amputation is 15 to 46 times higher in diabetics than in persons who do not have diabetes mellitus.
[123]
Cardiac Autonomic Dysfunction and Risk of Silent Myocardial ...
Oct 17, 2023 · In a large cohort of adults with type 2 diabetes, CAN was significantly associated with an increased risk of incident SMI.
[124]
Nociplastic pain and central sensitization in patients with chronic ...
While central sensitization is the major underlying mechanism of nociplastic pain,, it is also common in neuropathic pain. Nociplastic pain is defined ...
[125]
Chronic Inflammatory Demyelinating Polyneuropathy
Untreated, 30% of patients may become wheelchair-dependent. The incidence of CIDP is about 1-2 per 100,000 people annually, with a prevalence of up to 9 per ...
[126]
Prevalence of Depression and Anxiety Among Adults With Chronic ...
Mar 7, 2025 · This study suggests that the prevalences of depression and anxiety among adults with chronic pain are approximately 40%.
[127]
Uremic neuropathy: clinical features and new pathophysiological ...
Neuropathy is a common complication of end-stage kidney disease (ESKD), typically presenting as a distal symmetrical process with greater lower-limb than upper ...
[128]
Interventional effects of exercise on neuropathy in patients with ...
Apr 14, 2025 · Some studies have shown that exercise intervention can reduce the rate of deterioration of neuropathy in diabetic patients by 20% [4]. A study ...Missing: polyneuropathy | Show results with:polyneuropathy